Human Papillomavirus (HPV) Vaccine Research in the Infections and Immunoepidemiology Branch
IIB Research Areas
Human papillomavirus (HPV) causes a number of cancers, including cervical cancer, which is one of the leading causes of cancer incidence and death globally, and oropharyngeal cancer (OPC), which is one of the fastest increasing cancers in the Unites States. Researchers in the Infections and Immunoepidemiology Branch (IIB) are investigating primary prevention via prophylactic HPV vaccination. Selected studies include:
HPV Vaccine Trial in Costa Rica
A randomized, controlled phase III trial of a vaccine to prevent human papillomavirus (HPV) 16 and 18 infections and their associated cervical lesions in Costa Rica. Learn more about the HPV Vaccine Trial in Costa Rica.
Study of HPV Vaccine Efficacy at Extracervical Sites
A study to determine the impact of HPV vaccination in preventing infections in the oral, vulvar, and anal regions. Learn more about HPV vaccine effiicacy at extracervical sites.
PRIMAVERA*-ESCUDDO Trial to Compare One Dose of Bivalent HPV Vaccine to Three Doses of Quadrivalent Vaccine
A non-inferiority trial comparing immunogenicity from one dose of bivalent HPV vaccine in girls to three doses of quadrivalent vaccine in women. Learn more about The PRIMAVERA*-ESCUDDO Trial.
Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines—The ESCUDDO* Study
Study to evaluate the efficacy of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines. Learn more about the ESCUDDO Study.